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Benign epilepsy with centrotemporal spikes (BECTS), also known as benign rolandic epilepsy (BRE) of childhood represents
15% of all childhood epilepsies [Handbook of Epilepsy Treatment (2000)]. A majority of these patients do no require treatment;
however, in those cases where treatment is justified, the most efficacious medication with a benign safety profile should be
selected. We present three clinical cases of otherwise healthy children with BECTS who were treated only with levetiracetam.
All three of these children remain seizure-free and are experiencing no reported side effects.
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INTRODUCTION
Benign epilepsy of childhood with centrotempo-
ral spikes (BECTS), also known as benign rolandic
epilepsy (BRE) is an epilepsy syndrome begin-
ning at age 3–12 years in otherwise normal chil-
dren. It represents 15% of all childhood epilepsies1.
Most seizures affect the face and oropharyngeal
muscles, but children may also experience convul-
sions. The electroencephalogram (EEG) may be
normal, but typically reveals large epileptic spikes
in the rolandic region. Treatment with antiepilep-
tic drugs (AEDs) is not always required because
seizures are infrequent, tend to occur during sleep,
and the syndrome remits by age 16. However, fac-
tors in favour of treatment include a young age
of onset, a short interval between the first three
seizures, generalised convulsive seizures, and daytime
seizures2.
One major argument against AED treatment in this
population is the disadvantage of medication side
effects. Children who require treatment traditionally
receive carbamazepine or valproic acid3. Gabapentin,
a traditionally safer medication, suggested superiority
over placebo in a recent double-blind, randomised,
placebo-controlled trial, but the intent to treat analy-
sis did not reach statistical significance (P = 0.085)4.
Lamotrigine has also been reported for use in BECTS.
In a retrospective study (n = 4) all of the children
remained asymptomatic; however, the follow-up was
less than 6 months5.
However, seizures can warrant treatment when
frightening and distressing to child or parents. Ad-
ditionally, whether intellectual deterioration results
from partial seizures remains unclear6 and tonic
clonic seizures expose the child to injury and may in-
crease the risk of sudden unexpected death in epilepsy
(SUDEP)7.
Potential advantages of levetiracetam for the pae-
diatric population include this novel drug’s lack of
non-linear elimination kinetics, autoinduction kinet-
ics, drug–drug interactions, significant protein bind-
ing (<10%), or reactive metabolites such as epoxides,
-enes, or oxides8. Levetiracetam does not cause the
weight gain and thinning of hair seen with valproic
acid, nor is it extensively metabolised in the liver9.
Carbamazepine has a risk of rash of 10%10, while
the risk of rash with levetiracetam approximates
placebo11. Levetiracetam also takes a relatively short
time to achieve therapeutic dose, unlike lamotrigine
which can take 5–6 weeks; and lamotrigine has a 6%
chance of rash5.
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CASE 1
SG presented 18 December 2000, at age 4 years 6
months with two episodes of right arm partial seizures
lasting approximately 20 seconds. The first occurred
while eating; her right arm shook and she suddenly
fell backwards. She did not lose consciousness, but
complained of a headache. Emergency room evalua-
tion was unremarkable. The next day, during a nap at
school, she had abnormal movements of her right arm.
When she awoke, she was unable to move the right
arm for about 10 minutes.
The patient was a 6 lb 7 oz product of a 40-week
gestation, born via Caesarean section because of
pre-eclampsia. Developmental milestones were nor-
mal. Apart from multiple ear infections, she has
no significant past medical history. Family history
was remarkable for childhood seizures in a maternal
cousin. In addition, a great grandmother had grand
mal seizures.
Physical and neurological examinations were nor-
mal. EEG revealed abundant focal spike discharges
from the left centrotemporal region while awake. The
brain MRI was normal. The patient began levetirac-
etam 250 mg each evening. Other AEDs were ex-
cluded because of their more toxic side effect profiles.
A repeat EEG on 14 September 2001 was normal. She
has not reported any side effects and has been seizure
free since December 2000.
CASE 2
KC is a 6-year-old girl who presented in June 2000
with two episodes of twitching of the left face, arm,
and leg accompanied by jabbery speech. Both episodes
occurred during sleep. One month earlier her mother
recalled an episode of drooling in bed.
The patient was a 7 lb 7 oz produce of a 37-week ges-
tation born via scheduled Caesarean section because
of prior Caesarean section. Developmental milestones
were normal. She had no significant past medical his-
tory or family history of epilepsy. Neurologic exam
was normal. An EEG on 28 June 2000 revealed bi-
lateral centrotemporal spikes. Brain MRI was normal.
The diagnosis of BECTS was made and the child was
followed without treatment. However, over the next
year, the seizures became more frequent and occurred
as often as every other day. Levetiracetam was cho-
sen for treatment because of its benign safety profile.
Levetiracetam was initiated at 500 mg each evening
at the beginning of June 2001. A repeat EEG on 15
June 2001 was normal. A third EEG on 7 December
2001 was also normal. The patient had one seizure
in November 2001, characterised by left facial drool-
ing. EEG at her follow-up visit on 7 October 2002 re-
vealed frequent left centrotemporal spikes consistent
with BRE. Her dose was increased to 750 mg each
evening, and when the patient was seen on 5 Septem-
ber 2002, increased to 1000 mg each evening. She has
had no drug related adverse effects or further seizures.
CASE 3
JA is a 10-year-old girl who had her first seizure
while asleep in May 2000 and was subsequently di-
agnosed with BRE by another physician. The seizures
were described as occurring within 2 hours of going
to sleep, accompanied with facial twitching and pro-
gressing into bilateral tonic stiffening of the arms and
legs. She was referred to us due to the refractory na-
ture of these seizures, as she has four seizures in May
2002. Her past medical history, family history, neu-
rological exam and MRI were negative. The EEG re-
vealed right centrotemporal spikes. She began taking
levetiracetam, reaching a final dose of 500 mg in the
morning and 1000 mg in the evening over a 2-week
interval. She remains seizure-free and reports no side
effects.
DISCUSSION
The Food and Drug Administration approved levetira-
cetam in November 1999 as adjunctive treatment
for partial onset seizures in adults based on three
multicenter, randomised, double-blind, placebo-
controlled clinical studies in patients with refrac-
tory partial seizures with or without secondary
generalisation12–14. In addition, a safety, tolerabil-
ity, and pharmacokinetic study of levetiracetam in
23 paediatric patients (ages 6–12 years) with partial
onset seizures demonstrated that 12/23 (52%) had
a ≥50% reduction in seizure frequency and 5/23
(22%) had a ≥75% improvement. Two patients (9%)
were seizure free. The most common side effects
were headache, infection, somnolence, anorexia,
and nervousness15. Pharmacokinetic studies of these
children revealed an increased clearance of levetirac-
etam (1.43 ± 0.36 ml/min/kg) compared to adults
(1.13±0.30 ml/min/kg), suggesting that children may
require a higher daily maintenance dose than adults16.
All three children in this series had recurrent
seizures due to BECTS. After beginning levetirac-
etam, one child had one seizure; otherwise all the
children were seizure free. Sedation was the only side
effect, and this was mild, well tolerated, and transient.
These encouraging results warrant consideration of
levetiracetam for children with BECTS who require
treatment. A formal clinical trial of levetiracetam in
children with BECTS should be considered.
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